Showing results (11-20 of 41) with videos related to

Sort By:
Pageof 5
Cancer Medicine|May 25, 2023
Randomized, Phase II study of pemetrexed plus bevacizumab versus pemetrexed alone after treatment with cisplatin, pemetrexed, and bevacizumab in advanced non-squamous, non-small cell lung cancer: TORG (thoracic oncology research group) 1321Takashi Kasai, Kiyoshi Mori, Yoichi Nakamura, et al.
Journal of Thoracic Disease|March 12, 2026
Relationship between immune-related adverse events and treatment outcome of immune checkpoint inhibitors for advanced non-small cell lung cancer: a retrospective cohort studyTakafumi Hashimoto, Takashi Karashima, Kosuke Kamada, et al.
BMC Cancer|January 4, 2022
Prognostic nomogram for patients with unresectable pancreatic cancer treated with gemcitabine plus nab-paclitaxel or FOLFIRINOX: A post-hoc analysis of a multicenter retrospective study in Japan (NAPOLEON study)Taro Shibuki, Toshihiko Mizuta, Mototsugu Shimokawa, et al.
International Journal of Clinical Oncology|May 20, 2023
Scoring model with serum albumin and CA19-9 for metastatic pancreatic cancer in second-line treatment: results from the NAPOLEON studyAzusa Komori, Satoshi Otsu, Mototsugu Shimokawa, et al.
Anticancer Research|July 7, 2021
Gemcitabine Plus Nanoparticle Albumin-bound Paclitaxel Versus FOLFIRINOX for Recurrent Pancreatic Cancer After ResectionHiroki Taguchi, Taiga Otsuka, Mototsugu Shimokawa, et al.
International Journal of Clinical Oncology|January 23, 2021
A multicenter propensity score analysis of FOLFIRINOX vs gemcitabine plus nab-paclitaxel administered to patients with metastatic pancreatic cancer: results from the NAPOLEON studyTaiga Otsuka, Tsuyoshi Shirakawa, Mototsugu Shimokawa, et al.
Pancreas|August 4, 2021
Gemcitabine Plus Nab-Paclitaxel Versus FOLFIRINOX in Locally Advanced, Unresectable Pancreatic Cancer: A Multicenter Observational Study (NAPOLEON Study)Shiho Arima, Machiko Kawahira, Mototsugu Shimokawa, et al.
Cancer Science|September 15, 2019
Exploration of potential prognostic biomarkers in aflibercept plus FOLFIRI in Japanese patients with metastatic colorectal cancerTetsuya Hamaguchi, Tadamichi Denda, Toshihiro Kudo, et al.
Anticancer Research|March 28, 2023
Conversion Surgery for Unresectable Pancreatic Cancer Treated With FOLFIRINOX or Gemcitabine Plus Nab-paclitaxelYasushi Ide, Taiga Otsuka, Mototsugu Shimokawa, et al.
Targeted Oncology|March 1, 2024
A Phase II Study of FOLFIRI Plus Ziv-Aflibercept After Trifluridine/Tipiracil Plus Bevacizumab in Patients with Metastatic Colorectal Cancer: WJOG 11018GToshihiko Matsumoto, Yoshiyuki Yamamoto, Masahito Kotaka, et al.
Pageof 5